TestAVec CSO Files patent for the manufacture of a pure viral vector.

Professor Mike Themis of Brunel University London – is the holder of a number of patents relating to gene therapy safety, safety testing and vector efficiency improvement. He was also involved in the production of a consensus paper published last year outlining the preferred future for gene therapy safety testing which was supported by most of the main players in the Gene Therapy field.

Professor Themis has also developed a gene therapy safety platform as a result of a research project backed by NC3R’s and funded by Novartis, GSK, Roche and others.

Professor Themis also led the research team that identified the presence of Impurities in viral vectors the results of which were published in Human Gene Therapy (https://doi.org/10.1089/hum.2024.121) and the paper has been downloaded almost 1,200 times in the past three months.

Having identified impurities that the Professor believes might be responsible for unexpected results from the use of vectors in gene therapy, he set out to design a Vector that has no impurities in and has now filed a patent for the method of doing this.

As Professor Themis points out – we use deionised or distilled water in many experiments to avoid any possible influences from impurities so isn’t it entirely logical to produce and, indeed use, the purest vector possible when developing vectors for CAR-T and Gene Therapy.

If you want to test your vector to see if impurities are present, contact us and we will be happy to assist.